ArticleOncotarget2017
MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX).
Kei Kawaguchi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
26 papers cite it
this papercites it